EVARF — Lombard Medical Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -50.06% | ||
| Return on Equity | -108.73% | ||
| Operating Margin | -237.33% | ||
Financial Summary
| Year End 31st Dec | Unit | 2012 | 2013 | 2014 | 2015 | 2016 | 2017E | 2018E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.17 | 6.96 | 13.28 | 15.11 | 12.17 | n/a | n/a | 13.63% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lombard Medical, Inc. is a medical device company. The Company is focused solely on the minimally invasive treatment of aortic disease. The Company partners with MicroPort Endovastec to offer Minos abdominal aortic aneurysm (AAA) stent-graft, the Hercules TAA stent graft and the Castor Branched Thoracic stent graft, in addition to its own Aorfix and Altura stent grafts. The Company’s products include Minos, Aorfix, Altura, Meridian, Hercules, Castor, and Hercules Balloon.
Directors
- Raymond Cohen NEC (62)
- Simon Hubbert CEO (45)
- William Kullback CFO (50)
- Peter Phillips CTO (62)
- David Milne DRC (58)
- Michael Carrel NED (50)
- Timothy Haines IND (61)
- Simon Neathercoat IND (65)
- Craig Rennie IND (64)
- John Rush IND (54)
- Last Annual
- December 31st, 2016
- Last Interim
- December 31st, 2016
- Incorporated
- January 16th, 2014
- Public Since
- April 25th, 2014
- No. of Employees
- 111
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 27,950,785
- Address
- Lombard Medical House, 4 Trident Park, DIDCOT, OX11 7HJ
- Web
- https://www.lombardmedical.com/
- Phone
- +44 1235750800
- Auditors
- Baker Tilly Virchow Krause, LLP
Upcoming Events for EVARF
Similar to EVARF
Aamaxan Transport
Pink Sheets on Nasdaq
ACCUSTEM SCIENCES
Pink Sheets on Nasdaq
ADM Tronics Unlimited
Pink Sheets on Nasdaq
Advanced Biomedical Technologies
Pink Sheets on Nasdaq
Aksys
Pink Sheets on Nasdaq
FAQ
As of Today at 19:13 UTC, shares in Lombard Medical are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Lombard Medical last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Lombard Medical share price has underperformed the S&P500 Index by -13.63% over the past year.
There is no consensus recommendation for this security.
Lombard Medical does not currently pay a dividend.
Lombard Medical does not currently pay a dividend.
Lombard Medical does not currently pay a dividend.
To buy shares in Lombard Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Lombard Medical had a market capitalisation of .
Here are the trading details for Lombard Medical:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: EVARF
Based on an overall assessment of its quality, value and momentum Lombard Medical is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lombard Medical. Over the past six months, its share price has underperformed the S&P500 Index by -16.56%.
As of the last closing price of $0.00, shares in Lombard Medical were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lombard Medical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Lombard Medical's management team is headed by:
- Raymond Cohen - NEC
- Simon Hubbert - CEO
- William Kullback - CFO
- Peter Phillips - CTO
- David Milne - DRC
- Michael Carrel - NED
- Timothy Haines - IND
- Simon Neathercoat - IND
- Craig Rennie - IND
- John Rush - IND